drugset / Trial / NCT00632970
Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals
RandomizedParallel-groupOpen-labelTreatment
Summary
This program is designed to study the efficacy, safety, lipid effects and tolerability of raltegravir compared to lopinavir/ritonavir, in patients with HIV-I infection who have not received prior antiretroviral therapy. All patients will receive concomitant therapy with Truvada.
Timeline
- Start
- 2008-02
- Primary completion
- 2010-02
- Completion
- 2010-06
Outcome
Outcome not reported
Stopped: “no patients completed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lopinavir/Ritonavir | Unknown | 100 mg | — |
| Comparator | Lopinavir/Ritonavir | Unknown | 400 mg | — |
| Subject | Raltegravir | Other / unclassified | 400 mg | — |
| Background | Truvada | Unknown | 200 mg | — |
| Background | Truvada | Unknown | 300 mg | — |